Yahoo Finance Calithera's Kidney Cancer Candidate Gets Fast Track Status
Calithera Biosciences, Inc. CALA announced that the FDA has granted Fast Track designation to its lead candidate, CB-839. The candidate is being developed in combination with Exelixis, Inc.’s EXEL Cabometyx (cabozantinib) for the treatment of metastatic kidney cancer.
The FDA grants a fast track designation to expedite a candidate’s development and review, which treats serious and unmet medical conditions. With this designation, a candidate is expected to be granted a priority review once it files a new drug application.
Calithera’s shares have underperformed the industry so far this year. The stock has lost 25.7% compared with the industry’s fall of 0.6%.
Calithera’s CB-839, a selective, potent inhibitor of glutaminase, is being evaluated in a phase II study – CANTATA – in combination with Cabometyx in clear cell renal cell carcinoma (“RCC”) in patients previously treated with at least one vascular endothelial growth factor tyrosine kinase inhibitor or the combination of Bristol-Myers’ BMY Opdivo (nivolumab) and Yervoy (ipilimumab).
The study is currently enrolling patients and the primary endpoint is improved progression free survival.
Per the press release, there are a number of therapies approved for RCC. However, there still remains a significant unmet need in advanced stage patients who have failed prior systemic therapy.
Kidney cancer is among the top 10 common cancer types globally, per the American Cancer Society. The organization predicts that an estimated 65,340 new patients will be diagnosed with the disease in the United States in 2018. Moreover, 14,970 deaths will be caused due to this cancer.
Calithera Biosciences, Inc. Price
Calithera Biosciences, Inc. Price | Calithera Biosciences, Inc. Quote
Zacks Rank & Stock to Consider
Calithera carries a Zacks Rank #4 (Sell).
A better-ranked stock in the health care sector is Ligand Pharmaceuticals Incorporated LGND, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Ligand’s earnings per share estimates moved up from $3.78 to $4.40 for 2018 and from $4.75 to $5.32 for 2019 in the last 60 days. The company delivered a positive surprise in three of the trailing four quarters with an average beat of 24.88%. Share price of the company has risen 24.3% so far this year.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY) : Free Stock Analysis Report
Exelixis, Inc. (EXEL) : Free Stock Analysis Report
Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report
Calithera Biosciences, Inc. (CALA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
